LifeStance Health (LFST) EBIT (2020 - 2026)

LifeStance Health has disclosed EBIT across 7 years of filings, most recently posting $22.3 million for Q1 2026.

• In Q1 2026, EBIT rose 1289.28% year-over-year to $22.3 million; the TTM figure through Mar 2026 stood at $44.8 million (up 438.66% YoY), while the FY2025 annual figure was $24.1 million, up 176.39% from the prior year.
• EBIT rose to $22.3 million in Q1 2026, from $18.1 million in the prior quarter.
• Over the last five years, EBIT for LFST reached as high as $113.5 million in Q4 2023 and fell as low as -$74.4 million in Q3 2023.
• The 5-year median for EBIT is -$15.9 million (2024), against an average of -$14.0 million.
• Annual changes were most pronounced in 2022 — EBIT slumped 7261.07% — and 2025, when it soared 15665.96%.
• A 5-year view of EBIT shows it stood at -$46.0 million in 2022, then soared by 346.63% to $113.5 million in 2023, then sank by 99.07% to $1.1 million in 2024, then surged by 1607.65% to $18.1 million in 2025, then rose by 23.22% to $22.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $22.3 million, $18.1 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.